Brain Tumor Clinical and Clinical Research Program

脑肿瘤临床和临床研究计划

• 批准号: 7970212
• 负责人: Howard Fine
• 金额: $ 293.05万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7970212
• 关键词: Adult; Biotechnology; Brain; Brain Neoplasms; CC-5013; Cardiology; Central Nervous System Neoplasms; Child; Clinic; Clinical; Clinical Research; Clinical Trials; Communities; Consult; Consultations; Data; Disease; Distant; District of Columbia; Endocrinology; Ensure; Fellowship; Glioma; Group Practice; Hospitals; Institution; Joints; LY317615; Laboratories; Mails; Malignant Glioma; Malignant Neoplasms; Malignant neoplasm of brain; Medical Oncology; Medical Records; Medical center; Medicine; Mission; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke; Natural History; Neurology; Neurosurgeon; Nurse Practitioners; Nursing Research; Oncologic Nursing; Oncologist; Oncology Nurse; Operative Surgical Procedures; Ophthalmology; Pain; Patients; Pharmacologic Substance; Physicians; Pituitary Neoplasms; Primary Brain Neoplasms; Protocols documentation; Psychiatry; Radiation; Radiation Oncology; Radiology Specialty; Recruitment Activity; Rehabilitation therapy; Research; Research Ethics Committees; Research Infrastructure; Research Personnel; Research Training; Resources; Running; Scientist; Screening procedure; Second Opinions; Services; Social Work; Specialist; Spinal Cord Neoplasms; Stroke; Talampanel; Tamoxifen; Time; Tissues; Training; Training Programs; Translational Research; Travel; United States National Institutes of Health; Velcade; Washington; Work; clinical care; effective therapy; follow-up; hemangioblastoma; improved; multidisciplinary; nervous system disorder; neuro-oncology; neurosurgery; novel; novel therapeutics; oncology service; palliation; pre-clinical; programs; standard care; tumor

The NOB has made substantial progress towards building an infrastructure necessary for fulfilling its mission of developing new and improved therapies for children and adults with brain and spinal cord tumors. Below are partial lists of accomplishments in the building of the Brain Tumor Clinical and Clinical Research Program: Established an NIH-wide multidisciplinary Brain Tumor Clinic with active participation from three different NCI Branches (ROB, MOCRU, CCRLP), five different NIH Institutions (NCI, NINDS, NEI, NHLBI, NIMH), and five different Clinical Center Programs (Neuroradiology, Psychiatry, Pain and Palliation, Rehabilitation Medicine, Social Work). Expertise represented in the clinic includes Medical Oncology, Radiation Oncology, Neurosurgery, Neurology, Ophthalmology, Cardiology, Psychiatry, Endocrinology, Social Work, and Rehabilitation Medicine; Assembled a primary neuro-oncology clinical care/research team, which now consists of 4 neuro-oncologists, 6 NOB-trained neuro-oncology nurse practitioners, 3 research nurses, 2 neuro-oncology fellows, 2 patient coordinators, 2 clinical trials specialists and 5 data managers; Established a robust neuro-oncology consultation service, in which local/regional patients are seen and followed at the NIH (all patients are accrued to a CNS tumor natural history protocol; distant patients may just have radiology/medical records reviewed; Serving as Chair of the Search Committee, Howard Fine helped recruit two new tenure track clinician/scientist brain tumor neurosurgeons to NINDS/NCI leading to a total of 5 clinically active brain tumor neurosurgeons in the Surgical Neurology Branch, NINDS; Activated more than 30 IRB approved clinical trials with an additional 4 expected to be approved in the coming motnhs, for a total of 30 protocols compared to just 1 protocol existing for primary brain tumors at the NIH when the NOB was formed in 2000 (a prior radiation protocol that had accrued <10 patients in total). In short, the NOB has been able to accomplish the following in a short period of time (and continues): Accrues more than 200 primary brain tumor patients to NOB IRB-approved clinical trials per year; Saw >500 new primary brain tumor patients (almost all gliomas) and between 2000-3000 follow-up patients over the last 12 months, up from < 10 patients with malignant brain tumor seen at NIH in the year before the NOB was formed (1999). Additionally, the NOB reviews 2-6 new mail-in patient consults per week. Provides almost all neuro-oncology services for Walter Reed Medical Center, the Portsmouth Naval Hospital, and the Naval Medical Center in Bethesda; Established close collaborative clinical programs with Johns Hopkins Medical Center, George Washington Medical Center, Fairfax Inova and Washington Hospital Center and a wide array of private neurosurgical, radiation, and oncology practice groups locally and nationally; Created one of only a few organized neuro-oncology fellowship training programs in the United Statesa three-institution joint research training program between the NIH, Johns Hopkins Medical Center, and Childrens National Medical Center in Washington, D.C.; Identified five compounds through the preclinical screening program that have since been brought forward to clinical trials at the NIH (CC8490, LY317615, Velcade + Tamoxifen, CC5013, Talampanel, MLN518, Sunitinib). Activated more than 9 clinical trials as a direct result of translational work performed within the Neuro-Oncology Laboratory.

NOB在建设必要的基础设施方面取得了实质性进展， 履行其使命，为儿童和成人开发新的和改进的治疗方法， 脑和脊髓肿瘤。以下是在建设和平方面取得的部分成就。 脑肿瘤临床和临床研究计划：建立了一个NIH范围的 来自三个不同NCI的多学科脑肿瘤诊所的积极参与 分支机构（ROB，MOCRU，CCRLP），五个不同的NIH机构（NCI，NINDS，NEI，NHLBI，NIMH）， 和五个不同的临床中心计划（神经放射学，精神病学，疼痛和姑息， 康复医学、社会工作）。诊所所代表的专业知识包括医疗 肿瘤学、放射肿瘤学、神经外科学、神经病学、眼科学、心脏病学、精神病学， 内分泌学、社会工作和康复医学;组建了一个主要的神经肿瘤学 临床护理/研究团队，目前包括4名神经肿瘤学家，6名NOB培训 神经肿瘤学执业护士，3名研究护士，2名神经肿瘤学研究员，2名患者 协调员、2名临床试验专家和5名数据管理员; 神经肿瘤学咨询服务，在该服务中， NIH（所有患者均符合CNS肿瘤自然史方案;远处患者） 可能只是有放射学/医疗记录审查;担任搜索委员会主席， 霍华德费恩帮助招募了两名新的终身教职临床医生/科学家脑肿瘤神经外科医生 到NINDS/NCI，总共有5名临床活跃的脑肿瘤神经外科医生， NINDS外科神经病学分支;激活了30多项IRB批准的临床试验， 预计将在即将到来的国家卫生部批准另外4项议定书，总共30项议定书 相比之下，当NOB在NIH时， 形成于2000年（之前的放射治疗方案，总共累积了10名患者）。 简而言之，NOB能够在短时间内完成以下工作（以及 继续）：将200多名原发性脑肿瘤患者纳入NOB IRB批准的临床研究 每年有500例新的原发性脑肿瘤患者（几乎所有神经胶质瘤）， 在过去12个月内，2000-3000名随访患者，从10名患者增加到 在NOB成立前一年（1999年），NIH发现了恶性脑肿瘤。 此外，NOB每周审查2-6例新的邮寄患者咨询。提供几乎所有 沃尔特里德医疗中心，朴茨茅斯海军医院和 贝塞斯达的海军医疗中心;与约翰斯建立了密切合作的临床项目 霍普金斯医疗中心、乔治华盛顿医疗中心、费尔法克斯伊诺瓦和华盛顿 医院中心和广泛的私人神经外科，放射和肿瘤学实践 创建了为数不多的有组织的神经肿瘤学奖学金之一 美国的三个机构联合研究培训计划 美国国立卫生研究院、约翰霍普金斯医学中心和美国国家儿童医学中心之间的合作， 华盛顿，华盛顿特区通过临床前筛选程序鉴定了五种化合物， 已经在NIH进行了临床试验（CC 8490，LY 317615，Velcade + 他莫昔芬，CC 5013，Talampanel，MLN 518，舒尼替尼）。作为一个活跃的临床试验超过9个 在神经肿瘤学实验室内进行的翻译工作的直接结果。